undamentalytics Newsletter
Sign in

Caribou Biosciences, Inc. cash flow statement

In fiscal 2025, Caribou Biosciences, Inc.'s operations generated −$111m of cash; it spent $1.4m on capital projects, leaving free cash flow of −$112m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−32−33−33−91−93−138−111−96
Depreciation and amortisation11124443
Stock-based pay1131214171311
Capital spending10261251−0
Free cash flow−33−34−35−97−105−143−112−96
Free cash flow after stock pay−34−35−38−109−119−160−125−106
Shares issued———0115424

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: CRBU vs IRDCRBU vs RLAYCRBU vs HYFT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Caribou Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Caribou Biosciences, Inc.